Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease

Importance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.Methods: Full retrospective data from advanced PD patients before and after an acute levodopa chal...

Full description

Bibliographic Details
Main Authors: Francesco Cavallieri, Carla Budriesi, Annalisa Gessani, Sara Contardi, Valentina Fioravanti, Elisa Menozzi, Serge Pinto, Elena Moro, Franco Valzania, Francesca Antonelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2020.616062/full
id doaj-c6bf173dc2014c8a8061c8e44d0e9af6
record_format Article
spelling doaj-c6bf173dc2014c8a8061c8e44d0e9af62021-02-05T06:39:11ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-02-011110.3389/fneur.2020.616062616062Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's DiseaseFrancesco Cavallieri0Francesco Cavallieri1Carla Budriesi2Carla Budriesi3Annalisa Gessani4Annalisa Gessani5Sara Contardi6Sara Contardi7Valentina Fioravanti8Elisa Menozzi9Elisa Menozzi10Elisa Menozzi11Serge Pinto12Elena Moro13Franco Valzania14Francesca Antonelli15Francesca Antonelli16Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyClinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalyDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyAzienda Ospedaliero Universitaria di Modena, Modena, ItalyDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyAzienda Ospedaliero Universitaria di Modena, Modena, ItalyDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyAzienda Ospedaliero Universitaria di Modena, Modena, ItalyNeurology Unit, Neuromotor and Rehabilitation Department, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyAzienda Ospedaliero Universitaria di Modena, Modena, ItalyDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United KingdomAix Marseille Univ, CNRS, LPL, Aix-en-Provence, FranceDivision of Neurology, Centre Hospitalier Universitaire (CHU), Grenoble Alpes University, Grenoble Institute of Neurosciences, Grenoble, FranceNeurology Unit, Neuromotor and Rehabilitation Department, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyAzienda Ospedaliero Universitaria di Modena, Modena, ItalyImportance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.Methods: Full retrospective data from advanced PD patients before and after an acute levodopa challenge were collected. Acoustic analysis of spontaneous monologue and sustained phonation including several quantitative parameters [i.e., maximum phonation time (MPT); shimmer local dB] as well as the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items) and the Clinical Dyskinesia Rating Scale (CDRS) were performed in both the defined-OFF and -ON conditions. The primary outcome was the changes of speech parameters after levodopa intake. Secondary outcomes included the analysis of possible correlations of motor features and levodopa-induced dyskinesia (LID) with acoustic speech parameters. Statistical analysis included paired t-test between the ON and OFF data (calculated separately for male and female subgroups) and Pearson correlation between speech and motor data.Results: In 50 PD patients (male: 32; female: 18), levodopa significantly increased the MPT of sustained phonation in female patients (p < 0.01). In the OFF-state, the UPDRS part-III speech item negatively correlated with MPT (p = 0.02), whereas in the ON-state, it correlated positively with the shimmer local dB (p = 0.01), an expression of poorer voice quality. The total CDRS score and axial subscores strongly correlated with the ON-state shimmer local dB (p = 0.01 and p < 0.01, respectively).Conclusions: Our findings emphasize that levodopa has a poor effect on speech acoustic parameters. The intensity and location of LID negatively influenced speech quality.https://www.frontiersin.org/articles/10.3389/fneur.2020.616062/fullacoustic analysisdysarthriadyskinesiaslevodopaParkinson's diseasespeech
collection DOAJ
language English
format Article
sources DOAJ
author Francesco Cavallieri
Francesco Cavallieri
Carla Budriesi
Carla Budriesi
Annalisa Gessani
Annalisa Gessani
Sara Contardi
Sara Contardi
Valentina Fioravanti
Elisa Menozzi
Elisa Menozzi
Elisa Menozzi
Serge Pinto
Elena Moro
Franco Valzania
Francesca Antonelli
Francesca Antonelli
spellingShingle Francesco Cavallieri
Francesco Cavallieri
Carla Budriesi
Carla Budriesi
Annalisa Gessani
Annalisa Gessani
Sara Contardi
Sara Contardi
Valentina Fioravanti
Elisa Menozzi
Elisa Menozzi
Elisa Menozzi
Serge Pinto
Elena Moro
Franco Valzania
Francesca Antonelli
Francesca Antonelli
Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
Frontiers in Neurology
acoustic analysis
dysarthria
dyskinesias
levodopa
Parkinson's disease
speech
author_facet Francesco Cavallieri
Francesco Cavallieri
Carla Budriesi
Carla Budriesi
Annalisa Gessani
Annalisa Gessani
Sara Contardi
Sara Contardi
Valentina Fioravanti
Elisa Menozzi
Elisa Menozzi
Elisa Menozzi
Serge Pinto
Elena Moro
Franco Valzania
Francesca Antonelli
Francesca Antonelli
author_sort Francesco Cavallieri
title Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
title_short Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
title_full Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
title_fullStr Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
title_full_unstemmed Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
title_sort dopaminergic treatment effects on dysarthric speech: acoustic analysis in a cohort of patients with advanced parkinson's disease
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2021-02-01
description Importance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.Methods: Full retrospective data from advanced PD patients before and after an acute levodopa challenge were collected. Acoustic analysis of spontaneous monologue and sustained phonation including several quantitative parameters [i.e., maximum phonation time (MPT); shimmer local dB] as well as the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items) and the Clinical Dyskinesia Rating Scale (CDRS) were performed in both the defined-OFF and -ON conditions. The primary outcome was the changes of speech parameters after levodopa intake. Secondary outcomes included the analysis of possible correlations of motor features and levodopa-induced dyskinesia (LID) with acoustic speech parameters. Statistical analysis included paired t-test between the ON and OFF data (calculated separately for male and female subgroups) and Pearson correlation between speech and motor data.Results: In 50 PD patients (male: 32; female: 18), levodopa significantly increased the MPT of sustained phonation in female patients (p < 0.01). In the OFF-state, the UPDRS part-III speech item negatively correlated with MPT (p = 0.02), whereas in the ON-state, it correlated positively with the shimmer local dB (p = 0.01), an expression of poorer voice quality. The total CDRS score and axial subscores strongly correlated with the ON-state shimmer local dB (p = 0.01 and p < 0.01, respectively).Conclusions: Our findings emphasize that levodopa has a poor effect on speech acoustic parameters. The intensity and location of LID negatively influenced speech quality.
topic acoustic analysis
dysarthria
dyskinesias
levodopa
Parkinson's disease
speech
url https://www.frontiersin.org/articles/10.3389/fneur.2020.616062/full
work_keys_str_mv AT francescocavallieri dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT francescocavallieri dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT carlabudriesi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT carlabudriesi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT annalisagessani dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT annalisagessani dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT saracontardi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT saracontardi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT valentinafioravanti dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT elisamenozzi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT elisamenozzi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT elisamenozzi dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT sergepinto dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT elenamoro dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT francovalzania dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT francescaantonelli dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
AT francescaantonelli dopaminergictreatmenteffectsondysarthricspeechacousticanalysisinacohortofpatientswithadvancedparkinsonsdisease
_version_ 1724284123348992000